PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pulmatrix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.42+0.06 (+4.41%)
Close on Oct 19, 2026
- Market cap
- $5.19M
- P/E (TTM)
- –
- Dividend yield
- –
Pulmatrix, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2020 | FY2016 | FY2015 | FY2014 | % of revenue |
|---|---|---|---|---|---|
| Toxicology Study Costs [Member] | $1.65M | – | – | – | 13.0% |
| Material Transfer Agreement [Member] | – | $0 | $77.00K | $0 | – |
| Long-Acting Muscarinic Agent Collaboration Agreement [Member] | – | $835.00K | $1.02M | – | – |
By region
From the segment and revenue-disaggregation notes of Pulmatrix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.